Fragment-based Drug Discovery

IOTA Pharmaceuticals Ltd and Vitas-M Laboratory Ltd, have joined forces to design and market the next generation of Fragment-based Drug Discovery libraries for early-stage drug discovery.

The IOTA Pharmaceuticals - Vitas-M Laboratory collaboration couples IOTA Pharmaceuticals analysis and screening platforms to Vitas-M Laboratory's established chemical synthesis capabilities, to produce a new 4,000-component Fragment-based Drug Discovery (FBDD) screening set. Together with the IOTA-Diverse 1,500 fragment library the total of available compounds for FBDD is 5,500 proprietary structures. Access to a diverse set of FBDD library compounds enables the rapid progression of new discovery programs from concept to optimised lead.

FBDD is a fast, efficient and productive route to NCE discovery. The combined technologies offer an extensive and reasonably-priced lead discovery tool kit for the pharma and biotech industry

Allium: This new library holds 4.000 structures for Fragment-Based Drug Discovery

 

 

.